Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI&#xA0;Trial

Atrial FibrillationTherapy and Intervention

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

JACC Cardiovasc Interv.

Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.

doi: 10.1016/j.jcin.2019.05.050.

Atrial Fibrillation

Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

Ann Intern Med.

Khan SU, Osman M, Khan MU, Khan MS, Zhao D, Mamas MA, Savji N, Al-Abdouh A, Hasan RK, Michos ED

doi: 10.7326/M19-3763.

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials

Clin Res Cardiol.

Duerschmied D, Brachmann J, Darius H, Frey N, Katus HA, Rottbauer W, Schäfer A, Thiele H, Bode C, Zeymer U

doi: 10.1007/s00392-018-1242-2.

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

N Engl J Med.

Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators

doi: 10.1056/NEJMoa1708454.

Atrial FibrillationTherapy and Intervention

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial

Circ Cardiovasc Interv.

Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP

doi: 10.1161/CIRCINTERVENTIONS.119.008349.

SPECIAL REPORT

Atrial FibrillationThrombosis and Stroke

Duale antithrombotische Therapie mit Xarelto^® bei Patienten mit nvVHF nach perkutaner Koronarintervention mit Stentimplantation: signifikant weniger schwere Blutungen als mit Triple-Therapie

Dieser Artikel wurde von Bayer (Schweiz) AG unterstützt.

doi: 10.1056/NEJMoa1611594. Epub 2016 Nov 14.

Atrial Fibrillation

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

Eur Heart J.

Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP

doi: 10.1093/eurheartj/ehz059.

Myocardial InfarctionTherapy and Intervention

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial

BMJ.

Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F

doi: 10.1136/bmj.k3793.

Therapy and Intervention

P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials

Am Heart J.

Kuno T, Ueyama H, Takagi H, Bangalore S

doi: 10.1016/j.ahj.2020.06.008.

Cardiovascular

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

Related content